ABSTRACT -Context -Orthotopic liver transplantation is an excellent treatment approach for hepatocellular carcinoma in well-selected candidates. Nowadays some institutions tend to Expand the Milan Criteria including tumor with more than 5 cm and also associate with multiple tumors none larger than 3 cm in order to benefit more patients with the orthotopic liver transplantation. Methods -The data collected were based on the online database PubMED. The key words applied on the search were "expanded Milan criteria" limited to the period from 2000 to 2009. We excluded 19 papers due to: irrelevance of the subject, lack of information and incompatibility of the language (English only). We compiled patient survival and tumor recurrence free rate from 1 to 5-years in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation according to expanded the Milan criteria from different centers. Results -Review compiled data from 23 articles. Fourteen different criteria were found and they are also described in detail, however the University of California -San Francisco was the most studied one among them. Conclusion -Expanded the Milan criteria is a useful attempt for widening the preexistent protocol for patients with hepatocellular carcinoma in waiting-list for orthotopic liver transplantation. However there is no significant difference in patient survival rate and tumor recurrence free rate from those patients that followed the Milan criteria.
INTRODUCTION
Orthotopic liver transplantation (OLT) is an excellent approach for hepatocellular carcinoma (HCC) in well-selected candidates (8, 47) . The most widely used criteria for patient selection are those proposed by Mazzaferro et al. (39) , the so-called Milan criteria (MC), (a single tumor up to 5 cm or up to 3 tumors none larger than 3,0 cm).
When MC were applied there was a significant improvement in survival over time for HCC patients undergoing OLT with a 5-year survival of 61,1% contrasting with previously observed 5-year survival rate of 25,3% in 1987. In recent years, however, some groups have argued that the MC are too restrictive, and exclude some HCC-patients from OLT despite the possibility of benefit. Expanded criteria can be defined by the use of OLT in recipients with tumors beyond the MC. The first description was published in 2001 by the group of the University of California (63) . In their study, 70 HCC-patients who underwent OLT were retrospectively evaluated on the basis of explants analysis, not pre-transplant radiology. In the 60 cases with either a single nodule up to 6.5 cm, or up to three nodules none larger than 4.5 cm, and total tumor diameter no more than 8 cm the 5-years overall survival was 75.2%. Forty-six out of the 60 patients (76%) had tumors that were within the MC and these had a 5-year survival of 72%.
Subsequently, in the past 10 years, some major new criteria was created expanding Milan criteria (EMC) such as: University of California, San Francisco (UCSF) Criteria (63) , Kyoto (57) , Asian (26) , Shanghai (13) , and others.
Our aim is to study the current situation of these several EMC proposed in order to clarify both this debate through a critical analysis of available data and addressed discussion of further parameters beyond number and size of tumors, focusing on patient survival rate and tumor recurrence free rate from 1 to 5-years after OLT.
METHODS
A systematic search of Medline (PubMED) database was performed to identify studies evaluating expanded criteria for patients with HCC submitted to liver transplantation. The search was restricted to papers written in English and published from 2000 to 2009. The keywords used were hepatocellular carcinoma, liver transplantation, expanded criteria, the UCSF criteria, Milan Criteria, and others. Only papers reporting cadaveric liver donors that evaluated expanded criteria on the basis of tumor number and size were selected. This search resulted in a total of 39 studies. Additionally, a full manual search from bibliographies of papers describing aspects beyond tumor number and size, and reports of consensus conference was also performed. Nineteen papers were excluded due to: irrelevance of subject, lack of information and incompatibility of language.
We compiled data focusing on patient survival rate and tumor recurrence free rate from 1 to 5-years. We also compared results between MC and EMC. A P<0.05 was considered statistic significant.
RESULTS
Twenty-three papers including centers from North and South America, Europe and Asia were compiled. Fourteen different EMC were found; however UCSF was the most studied (10, 11, 13, 26, 57, 63) . The patient survival rate and tumor recurrence-free rates from 1 to 5-years were shown in Table 1 .
We have shown the UCSF patient survival and tumor recurrence-free rates from 1 to 5-years comparing them with MC in Table 2 . No significance difference was found between the two groups.
DISCUSSION
HCC is a major health problem worldwide (31) . In the West 30%-40% of HCC cases are detected at early stages and treated with intention to cure, a figure that reaches 60% of the cases Mazzaferro et al. (38) 2009 283
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Single tumor ≤ 9 cm in diameter, 2-3 tumors with the largest ≤ 5 cm, a total tumor diameter ≤ 9 cm without macrovascular invasion, lymph node invasion and extrahepatic metastasis in Japan (31) . Surgical treatments are accepted as the standard of care for early tumors because they provide survival rates consistently better than their untreated counterparts (5-years survival rates of 40%-70% vs < 20%) (6, 31, 33, 34) . Resection of single tumors in patients with well-preserved liver function lead to remarkable outcomes (5-years survival exceeds 50%-60%) (34) . Early results after OLT in unselected patients with cirrhosis and HCC were poor, with early recurrence rates and 5-year survival of only 18%-49% (15, 21, 30, 37, 41, 43, 44, 46) . Several small studies in the early 1990s suggested that recurrence-free survival could be improved by restricting transplantation to patients with two-three nodules or a single tumor < 3-5 cm in diameter (1, 14, 51) . Two large retrospective studies (21, 24) confirmed that tumors > 5 cm had a high rate of post-transplantation recurrence, largely because of the association with vascular invasion and poor differention.
The MC is considered the gold standard for selection of the best HCC candidates for OLT after numerous external validations of the seminal proposed (39) . In fact, the MC as a restriction selection for patients with HCC have been confirmed as consistent by several other groups among more than 1,000 patients (2, 22, 29) . The MC were subsequently used by the United Network for Organ Sharing to assign the listing priority of patients presenting HCC.
On the other hand, some studies have recently suggested that the MC might be too restrictive, with relatively good results achieved when different proposals are used (Table 1) .
There are essential aspects that should be considered when treatments related to HCC are evaluate: (1) treatments that achieve survival rates higher than 50% in 5-years are considered effectives therapies, given the fact that studies have demonstrated the 3-years survival of early HCC to be about 50% (5, 32) ; (2) the deleterious impact of the progressive increase in the waiting list time has to be considered when the efficacy of OLT as a treatment for HCC is evaluated because of the risk of tumor progression and death during this period (33, 63) , and (3) it is well known that preoperative imaging techniques underestimated HCC staging in about 20% of cases, and thus the extrapolation of the histopathologic data to the preoperative scenario might be misleading (7) . Yao et al. (64) from UCSF, reported a 5-year survival of 75% in patients with single tumor as large as 6.5 cm or a maximum of three tumors up to 4.5 cm and a cumulative tumor burden < 8 cm. With mostly retrospective data, some groups have independently tested these criteria (10, 11, 37) . These results have, however, been challenged because of the use of explants pathology, rather than preoperative imaging, as a determinant for the definition of the tumor stage.
The UCSF proposal is the approach mostly tested; however, it has been challenged because of the use of explants pathology. Duffy et al. (11) and Yao et al. (64) recently published their results analyzing the survival rates and recurrence probabilities on the basis of the pre-OLT radiologic assessment.
Expansion of tumor criteria for transplantation risks including patients with higher-grade tumors or microvascular invasion who might have a higher risk of recurrence. Indeed, as observed in previous reports, we found that tumors that exceeded the MC criteria were more likely to have evidence of vascular invasion in the explants (21, 24) . However, interestingly, this finding only affected recurrence-free survival when there were >five tumors or a single tumor > 6 cm. Thus, this may reflect tumor mass and the degree of vascular invasion rather than the presence of vascular invasion itself.
Several studies have shown that some tumor patients transplanted outside of the UNOS and MC survive longer (9, 12, 16, 17, 18, 36, 44, 52) and as consequence, several proposals have been made to expand the HCC inclusion criteria (18, 28, 63, 64, 65) . However, the criteria proposed by the University of Pittsburgh and some groups in Europe are based, at least in part, on pathological features (nodal invasion, grade, vascular invasion) that are not usually available before transplantation (9, 21, 50, 68) . By contrast, the MC, UCSF and Onaca et al. (42) proposal rely on factors (tu- ITT = intention to treat ¥ = patient survival (PS) ² = recurrence free rate (RR) Staging refers to the method used for tumor staging. P = pretransplant radiology; R = explant tumor pathology; NA = not available mor size and number) that can be determined by preoperative imaging, however, such criteria must consider the limitations of imaging studies (7, 23, 48, 55, 56, 59, 60) . The continued improvement in imaging techniques may decrease the gap between imaging and pathology of HCC, although some understanding will certainly continue to exist (53) . Silva et al. (54) reported 281 cases of HCC in cirrhotic livers treated by OLT using a new criteria (up to three tumors, each no larger than 5 cm, and a cumulative tumor burden < 10 cm) with a 5-year survival rate of 57% based on the intention-to-treat principle. The 5-year survival rate was 63% among transplanted patients.
No difference in survival or in recurrence were found bet ween cases within and beyond the UCSF criteria and others. Although these results suggest that this expansion does not result in an impaired outcome, we understand that they need validation, given the relatively small number of patients. Microvascular invasion was the only factor that predicted poor survival in the multivariate analysis. Indeed, several studies have shown that the differentiation degree and microvascular invasion represent direct indicators of the biologic progression of HCC, being associated with tumor recurrence and poor long-term survival (9, 11, 18, 39, 40, 45) . Expansion of transplantation inclusion criteria should be made cautiously. Listing criteria for HCC should reflect the minimum acceptable recurrence-free survival rate and must reflect a consensus of transplantation community. Furthermore, the results need to be confirmed prospectively if criteria were liberalized to ensure that an unrecognized selection bias did not influence the results themselves. Finally, the societal benefit of expanding tumor criteria needs to be weighed against a relatively fixed donor organ supply and a growing demand for OLT for other indications, such as decompensated cirrhosis due to chronic hepatitis C, where long-term survival may be better.
In conclusion, the EMC is useful attempt for widening the preexistent protocol for patients with HCC in the waiting-list for OLT, however there is no significant difference in patient survival rate and tumor recurrence free rate from those patients that followed the MC. 
